The Myeloma Landscape in 2008: Highlights From the
American Society of Hematology 2007 Annual Meeting
American Society of Hematology 2007 Annual Meeting
This CME-certified Web-based enduring activity is based on information presented at the American Society of Hematology (ASH) 49th Annual Meeting that took place December 8-11, 2007, in Atlanta, Georgia. American Society of Hematology does not endorse any particular uses of this document. The American Society of Hematology is not responsible for the completeness or the accuracy of the transcribed materials in this document.
| Release date: January 2008 Expiration date: January 31, 2009 Estimated time to complete activity: 2.25 hours |
Read through all material and click "Begin Activity" at the bottom of the page. |
Jointly sponsored by
Support for this activity has been provided through an educational grant from
Activity Overview
The pace of change in myeloma is unprecedented. A review of clinical trials on ClinicalTrials.gov showed over 600 clinical trials in myeloma, of which more than half are actively recruiting. Many of these trials include investigational agents that are not commercially available, but a large number of trials include commercially available agents used in new combinations. Indeed, as the number of approved agents increases, the primary question will be how these agents work together to provide better efficacy and safety. Over the last several years, new strategies including novel agents combined with traditional chemotherapies have showed promising activity in numerous phase 2 trials, providing a rationale for phase 3 evaluation.
Educational Needs
Novel agents, often combined with traditional agents, have shown response rates approaching that of transplantation. Although myeloma is still considered incurable, the greater depth of response and longer time to progression (TTP), along with a growing array of options for second- and third-line therapy, has caused a re-evaluation of treatment strategies.
Key questions for the treating oncologist in 2008 will be the following:
- What are the key measures of efficacy?
- What is the efficacy and safety profile of these agents?
- What patient factors (eg, age, renal status, risk factors, comorbidities) affect choice of therapy?
- Do new combinations result in significant adverse effects not seen with either agent used alone?
- How do these new combinations affect stem-cell collection?
- Do new and more potent combinations affect the timing or indications of transplantation?
- What is the efficacy of these regimens in special populations (eg, the elderly; patients with a history of prior transplantation; patients with risk factors, such as elevated beta2-microglobulin; unfavorable cytogenetics; or impaired renal function)?
This activity has been designed to meet the educational needs of hematologic oncologists.
Educational Objectives
Upon completion of this activity, participants should be able to:
- List phase 3 trials reported at ASH in newly diagnosed myeloma
- List the arms of these trials and state primary endpoints
- State primary efficacy findings from these trials
- Describe adverse effects of therapies describes in these trials
- Identify promising phase 2 trials of novel combinations for newly diagnosed myeloma
Paul G. Richardson, MD View biography
Clinical Director, Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA
William I. Bensinger, MD View biography
Professor, University of Washington
Fred Hutchinson Cancer Research Center
Seattle, WA
Ann F. Mohrbacher, MD View biography
Assistant Professor of Medicine
The University of Southern California/Norris Cancer Center
Los Angeles, CA
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Curatio CME Institute LLC and ApotheCom Associates LLC. Curatio CME Institute LLC is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Curatio CME Institute designates this educational activity for a maximum of 2.25 AMA PRA Category 1 CreditsTM.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in this CME activity. To receive credit during the period January 2008 to January 31, 2009, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest, and (4) complete the activity evaluation form, including the certificate information section.
This CME activity is divided into three sections. Please complete the corresponding posttest questions and evaluations for the sections you wish to claim credit.
To obtain a certificate, you must receive a score of 70% or better on the posttest. The posttest can be accessed at the end of the activity.
You will then be able to print or store your AMA PRA Category 1 Credit certificate for this activity. Please e-mail any questions to cmeinfo@curatiocme.com
Medium
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
Disclosure
In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Paul G. Richardson, MD, has disclosed the following relevant financial relationships:
| Advisory Board: | Millennium Pharmaceuticals |
| Speaker Bureau: | Celgene, Inc, Millennium Pharmaceuticals |
Dr Richardson discusses the unlabeled or investigational use of commercial products.
William I. Bensinger, MD, has disclosed the following relevant financial relationships:
| Grant/Research Support: | Amgen, Celgene, Inc, Novartis |
| Speaker Bureau: | Celgene, Inc |
| Consultant: | Millennium Pharmaceuticals |
Dr Bensinger discusses the unlabeled or investigational use of commercial products.
Ann F. Mohrbacher, MD, has disclosed the following relevant financial relationships:
| Speaker Bureau: | Genentech, Celgene, Inc |
Dr Mohrbacher discusses the unlabeled or investigational use of commercial products.
Planning Committee
Kevin Flynn, MA, Managing Director, ApotheCom Associates LLC, has disclosed no relevant financial relationships.
Joyce Dimig, Associate Managing Editor, ApotheCom Associates LLC, has disclosed no relevant financial relationships.
Denise LaTemple, PhD, Vice President, Scientific Services, Curatio CME Institute LLC, has disclosed no relevant financial relationships.
Brett Mutschler, CME Director, Curatio CME Institute LLC, has disclosed no relevant financial relationships.
Lauren Showers, Program Coordinator, Curatio CME Institute LLC, has disclosed no relevant financial relationships.
Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US FDA. Curatio CME Institute, ApotheCom Associates, and Millennium Pharmaceuticals do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this activity are those of the faculty and do not necessarily represent the views of Curatio CME Instite, ApotheCom Associates, and Millenium Pharmaceuticals. Please refere to the official prescribing information for each product for discussion of approved indications, contraindictions, and warnings.
Generic Name |
Trade Name |
Approved Use (if any) |
Unapproved/ |
Marketed |
|
|
|
Bortezomib |
Velcade® |
Multiple myeloma (MM) patients who have received at least 1 prior therapy |
Front-line therapy in combination with melphalan-prednisone, with cyclophosphamide, with thalidomide-dexamethasone, or with lenalidomide-dexamethasone |
Lenalidomide |
Revlimid® |
In combination with dexamethasone in MM patients who have received at least 1 prior therapy |
Front-line therapy in combination with dexamethasone or with bortezomib-dexamethasone |
Thalidomide |
Thalomid® |
Front-line therapy in combination with dexamethasone |
Front-line therapy in combination with bortezomib |
Hardware/Software Requirements
- Javascript-enabled browser
- Active Internet connection
- Adobe Acrobat Reader
- Adobe Flash Player plugin v.8.0+
Privacy Policy
Curatio CME Institute collects the information provided by the user. The information is used to provide notification about upcoming programs and educational information that may be of interest to our users. The information is not shared with others for commercial purposes, unless prior permission has been granted by the user.
Curatio CME Institute may collect standard Web traffic data such as the time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation and issuance of certification of CME/CE tests submitted. By participating in the Web-based activity, you agree that Curatio CME Institute has full permission to provide this minimum subset of information to third parties as required by law.
For CME questions, please contact cmeinfo@curatiocme.com or call (610) 363-1619 ext. 113. If you experience technical difficulties, please contact helpdesk@axis-healthcare.com.